AI assistant
Vivesto — AGM Information 2012
Aug 24, 2012
3124_rns_2012-08-24_147de181-04e0-49ea-ae6c-790afdf031e6.pdf
AGM Information
Open in viewerOpens in your device viewer
2012-08-24
PRESS RELEASE
Notice of Annual General Meeting in Oasmia Pharmaceutical AB
The shareholders of Oasmia Pharmaceutical AB (publ ), 556332-6676, are invited to participate in the Annual General Meeting to be held on Monday, September 24, 2012 at 2 p.m. at Vallongatan 1, Uppsala, Sweden. The registration will start at 1.30 p.m.
Registration and notification
Shareholders who wish toparticipate in the Annual General Meeting must be recorded in the share register kept by Euroclear Sweden AB on Tuesday, September 18, 2012, and give notice of intent to participate to the company not later than 4 p.m. on Thursday, September 20, 2012 by letter to Oasmia Pharmaceutical AB, Vallongatan 1, SE -752 28 Uppsala, Sweden, by fax: +46 18 51 08 73 or by e-mail: [email protected]m, including the number of assistants.
Shareholders that have their shares registered in the name of a nominee must, in additi on to giving notice of participation in the meeting, temporarily be recorded in the share register in their own names (so called voting -rights registration) to be able to participate in the General Meeting. Such registration must be effectuated on Tuesday, September 18, 2012.
Shareholders represented by an Agent shall to the Agent issue a written, dated proxy and shall submit the proxy to the company prior to the Annual General Meeting. The proxy and other eventual authorization documents, such as registr atons, shall be available at the Meeting. Such authorization documents should also be attached to the notice. For those who wish to be represented by agents, the company will provide proxies which will be available on the company website,www.oasmia.com.
The company€s shares are issued in one series. All shares carrying equal voting rights at the General Meeting. There are in total 57 240 631 shares in the company, accordingly there are in total 57 240 631 votes. The company holds no treasury shares.
Uppsala, August, 2012 The Board of Directors
About Oasmia Pharmaceutical AB
OasmiaPharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well established cytostatics which, in comparison with current alternatives, show improved p roperties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company share is listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange .
For more information, please contact: Maria Lund•n, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: [email protected]mPhone: +46 (0) 18 50 54 40.Information is also available atwww.oasmia.com www.nasdaqomxnordic.comwww.boerse-frankfurt.de
€Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submittedfor publication at9.00a.m. CET onAugust 24.•